Is BeyondSpring, Inc. overvalued or undervalued?

As of 29 December 2021, BeyondSpring, Inc. has moved from a grade of "does not qualify" to "risky," indicating a significant downgrade in its valuation outlook. The company appears to be overvalued given its negative financial metrics, including a P/E ratio of -15.46 and an EV to EBITDA ratio of -7.12. Additionally, the Price to Book Value stands at -2.42, reflecting substantial underlying issues with capital employed and book value.
In comparison to its peers, BeyondSpring's valuation metrics are less favorable. For instance, ASP Isotopes, Inc. has a P/E ratio of -24.01, while Journey Medical Corp. shows a P/E of -15.59, both indicating a challenging environment for these companies. Despite a strong performance over the past year with a stock return of 8.30%, it still lags behind the S&P 500's return of 10.26%. Overall, the combination of negative ratios and peer comparisons suggests that BeyondSpring, Inc. is overvalued in the current market context.